Newtrend Group Holding Co., Ltd. released its 2025 AGM circular outlining major agenda items for the 5 June 2026 meeting.

Key proposals

1. Profit distribution • The Board proposes no dividend or capitalisation of reserves for FY2025, citing capital needs for future expansion.

2. General mandates • Directors seek authority to issue new shares up to 20% of issued share capital and to repurchase up to 10% of shares during the mandate period.

3. Reallocation of IPO proceeds • Net proceeds from the June 2025 Hong Kong listing totalled HK$164.15 million. • Utilised to date: HK$38.17 million. • Unutilised: HK$125.98 million, of which HK$85.21 million originally earmarked for “seaweed dietary fibre and serine” will be redirected as follows: – HK$68.98 million to construct the Glycine Jingzhou production base (land, construction and equipment). – HK$16.23 million to a sucralose technology upgrade. • A further HK$1.09 million will be shifted within the R&D budget to expand the R&D centre, lifting its allocation to HK$18.06 million.

4. 2026 budget guidance • Administrative, selling and R&D expenses to be capped at about RMB70 million.

5. Board and governance changes • Dr. Zhang Xi, an industry executive with biotechnology and FDA experience, is nominated as an independent non-executive director with annual remuneration of RMB62,000. • Amendments to the Articles reflect the full conversion of 41.08 million domestic shares into H-shares, bringing total issued share capital to 96.23 million H-shares. • Pan-China Certified Public Accountants LLP and Confucius International CPA Limited are proposed as onshore and Hong Kong auditors for FY2026; estimated fees: RMB1.20–1.30 million and RMB0.50–0.60 million, respectively.

6. Remuneration overview (FY2025) • Directors received aggregate salaries and allowances of RMB2.22 million plus RMB34,000 in retirement contributions. • Supervisors received RMB0.58 million in remuneration and RMB0.07 million in retirement contributions.

The AGM will also vote on routine matters, including adoption of the 2025 annual report, work reports of the Board and Supervisory Board, and approval of the 2025 financial statements. H-shareholders on record as of 5 June 2026 may attend and vote; the register closes 1–5 June 2026.